Soumit Roy, PhD,
JonesTrading Institutional Services has appointed Soumit Roy, PhD, as managing director in investment banking, expanding its push into healthcare advisory and equity capital markets.
Roy, who previously led healthcare research at the firm, will now work with corporate clients on strategic advisory and capital-raising efforts, particularly across biotechnology. The relocate reflects a broader effort by JonesTrading to integrate its research and banking operations as competition intensifies for deals in the life sciences sector.
He joined JonesTrading in 2018 and played a central role in building out its healthcare research coverage, focapplying on areas such as immuno-oncology, genetic medicine, and neurodegenerative diseases. His transition into investment banking follows a common indusattempt pattern, where firms elevate sector analysts into client-facing advisory roles to leverage their scientific and market expertise.
“Soumit’s appointment reflects the strength of our integrated platform and our continued focus on delivering differentiated expertise to our clients,” declared CEO Alan Hill.
The hire comes as investment banks view to strengthen sector-specific capabilities amid uneven capital markets activity. While biotech funding has fluctuated in recent years, companies in the space continue to require specialized advisory services for public offerings, private placements, and partnerships. Firms with in-hoapply scientific expertise are often better positioned to compete for these mandates.
JonesTrading has been expanding its investment banking platform alongside its core trading business, which has historically focapplyd on block trading and institutional liquidity. Building out healthcare coverage is a strategic priority, given the sector’s complexity and ongoing demand for capital, particularly in emerging therapeutic areas.
Roy’s background includes postdoctoral research in clinical immunology at the Icahn School of Medicine at Mount Sinai. He holds a PhD in cancer research from the Albert Einstein College of Medicine, along with advanced degrees in developmental biology and molecular genetics.
His appointment underscores a wider trfinish across Wall Street, where firms are increasingly blfinishing research, data, and advisory capabilities to offer more specialized guidance to clients navigating volatile markets and complex regulatory environments.
Leave a Reply